Table 1.

Characteristics of patients with classified Burkitt and Burkitt‐like lymphoma (BL/BLL) according to the proportion of positive cells for caspase‐3

BL/BLL	High caspase‐3 group †	Low caspase‐3 group ‡	P‐value
Age	n = 19	n = 24
Median (range)	13 years (3–64)	64.5 years (5–85)
Child: ≤15 years	12 (63%)	5 (21%)	0.005
Senior: ≥60 years	1 (5%)	14 (58%)	<0.001
Sex	n = 19	n = 24	0.92
Male	9 (47%)	11 (46%)
Female	10 (53%)	13 (54%)
PS §	n = 19	n = 24	0.35
2–4	9 (47%)	8 (33%)
Site	n = 19	n = 24	0.09
Extranodal	15 (79%)	13 (54%)
Stage	n = 19	n = 24	0.977
III/IV	11 (58%)	14 (58%)
IPI score ¶	n = 19	n = 24	0.515
High risk	10 (53%)	15 (63%)
Treatment	n = 19	n = 21 †††	0.003
Group A ††	3 (16%)	13 (62%)
Group B ‡‡	16 (84%)	8 (38%)
bcl‐2	n = 19	n = 24	0.001
Negative	19 (100%)	14 (58%)
Ki‐67	n = 19	n = 24	0.058
Median percentage (range)	97.5% (95–100)	94% (82.5–100)
High group §§	11 (58%)	7 (29%)
Both Ki‐67 and caspase‐3	n = 19	n = 24	0.001
Median percentage (range)	65% (50–80)	50% (35–80)
High group ¶¶	14 (74%)	6 (25%)

^† High caspase‐3 group: positively‐stained tumor cells for caspase‐3, >30%.

^‡ Low caspase‐3 group: positively‐stained tumor cells for caspase‐3, ≤30%.

^{§ §} PS: performance status.

^¶ IPI: International Prognostic Index (age, clinical stage, performance status, lactate dehydrogenase level, and the number of extranodal disease sites): high risk (score, 3–5).

^{†† ††} Group A: patients with BL/BLL treated with cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) or the modified CHOP regimen.

^{‡‡ ‡‡} Group B: patients with BL/BLL treated with intensive short‐term chemotherapeutic regimen.

^§§ High group of Ki‐67: stained tumor cells, >95%.

^¶¶ High group both Ki‐67 and caspase‐3: stained cells for both Ki‐67 and caspase‐3, >55%.

^{††† †††} We were able to obtain clinical information of treatment from 21 of 24 low caspase‐3 group in BL/BLL.